Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-01

AUTHORS

Subhendra Chatterjee, Akiko Matsumura, Jaime Schradermeier, G. Yancey Gillespie

ABSTRACT

Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults and is invariably fatal. We have investigated the effect of cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide on survival of human malignant glioma cells in vitro and in vivo. Immunofluorescent analyses revealed the presence of αVβ3 integrin on U-87MG and U-373MG cells, but minimal expression on U-251MG cells. Treatment of U-87MG and U-373MG cells in vitro with cRGDfV (20 µg/ml), but not the linear peptide, resulted in the appearance of rounded and loosely attached cells with subsequent cell death. By comparison, neither this cyclic peptide nor its linear homolog had any significant effect on growth and morphology of U-251MG cells. The death of cRGDfV-treated (20 µg/ml) glioma cells was blocked by pretreatment (10 µM) of cells with DEVD-FMK and LEHD-FMK, inhibitors of caspase-3 and caspase-9, respectively. Moreover, when glioma cells grown as spheroids were treated with cRGDfV (50 µg/ml), spheroid formation was markedly reduced. Further, treatment of intracranial U-87MG tumors in scid mice with cyclic peptide significantly (p<0.001) prolonged their survival. These results indicated (i) that cRGDfV induced apoptosis of human glioma cells by binding αVβ3 integrin expressed on their cell surfaces and (ii) that cRGDfV may be an effective and non-toxic direct anti-tumor therapy for αVβ3-expressing GBMs. More... »

PAGES

135-144

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1006444300504

DOI

http://dx.doi.org/10.1023/a:1006444300504

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045558251

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10894366


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caspase 3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caspase 9", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caspase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Division", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Membrane", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intralesional", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, SCID", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptides, Cyclic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vitronectin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spheroids, Cellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "JCR Biopharmaceuticals, Inc., San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JCR Biopharmaceuticals, Inc., San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatterjee", 
        "givenName": "Subhendra", 
        "id": "sg:person.01102520331.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102520331.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JCR Pharmaceuticals Co., Ltd., Ashiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459663.b", 
          "name": [
            "JCR Pharmaceuticals Co., Ltd., Ashiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumura", 
        "givenName": "Akiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JCR Biopharmaceuticals, Inc., San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JCR Biopharmaceuticals, Inc., San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schradermeier", 
        "givenName": "Jaime", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ivision of Neurosurgery, Brain Tumor Research Laboratories, University of Alabama at Birmingham, Birmingham, AL, USA", 
          "id": "http://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "ivision of Neurosurgery, Brain Tumor Research Laboratories, University of Alabama at Birmingham, Birmingham, AL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gillespie", 
        "givenName": "G. Yancey", 
        "id": "sg:person.0734755026.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734755026.80"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/34214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029180304", 
          "https://doi.org/10.1038/34214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0498-408", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003109127", 
          "https://doi.org/10.1038/nm0498-408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002620050252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027317999", 
          "https://doi.org/10.1007/s002620050252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/356356a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010557586", 
          "https://doi.org/10.1038/356356a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-01", 
    "datePublishedReg": "2000-01-01", 
    "description": "Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults and is invariably fatal. We have investigated the effect of cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide on survival of human malignant glioma cells in vitro and in vivo. Immunofluorescent analyses revealed the presence of \u03b1V\u03b23 integrin on U-87MG and U-373MG cells, but minimal expression on U-251MG cells. Treatment of U-87MG and U-373MG cells in vitro with cRGDfV (20\u2009\u00b5g/ml), but not the linear peptide, resulted in the appearance of rounded and loosely attached cells with subsequent cell death. By comparison, neither this cyclic peptide nor its linear homolog had any significant effect on growth and morphology of U-251MG cells. The death of cRGDfV-treated (20\u2009\u00b5g/ml) glioma cells was blocked by pretreatment (10\u2009\u00b5M) of cells with DEVD-FMK and LEHD-FMK, inhibitors of caspase-3 and caspase-9, respectively. Moreover, when glioma cells grown as spheroids were treated with cRGDfV (50\u2009\u00b5g/ml), spheroid formation was markedly reduced. Further, treatment of intracranial U-87MG tumors in scid mice with cyclic peptide significantly (p<0.001) prolonged their survival. These results indicated (i) that cRGDfV induced apoptosis of human glioma cells by binding \u03b1V\u03b23 integrin expressed on their cell surfaces and (ii) that cRGDfV may be an effective and non-toxic direct anti-tumor therapy for \u03b1V\u03b23-expressing GBMs.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1006444300504", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "46"
      }
    ], 
    "keywords": [
      "glioblastoma multiforme", 
      "glioma cells", 
      "U-251MG cells", 
      "frequent malignant brain tumor", 
      "malignant brain tumors", 
      "U-373MG cells", 
      "anti-tumor therapy", 
      "human malignant glioma cells", 
      "malignant glioma therapy", 
      "malignant glioma cells", 
      "\u03b1v\u03b23 integrin", 
      "human glioma cells", 
      "U-87MG tumors", 
      "SCID mice", 
      "brain tumors", 
      "pretreatment of cells", 
      "glioma therapy", 
      "cRGDfV", 
      "subsequent cell death", 
      "minimal expression", 
      "immunofluorescent analysis", 
      "LEHD-FMK", 
      "therapy", 
      "tumors", 
      "cell death", 
      "death", 
      "U-87MG", 
      "survival", 
      "DEVD-FMK", 
      "spheroid formation", 
      "treatment", 
      "cells", 
      "inhibitor of caspase-3", 
      "cell surface", 
      "peptides", 
      "integrins", 
      "multiforme", 
      "significant effect", 
      "mice", 
      "adults", 
      "caspase-3", 
      "vitro", 
      "vivo", 
      "apoptosis", 
      "inhibitors", 
      "pretreatment", 
      "effect", 
      "caspase-9", 
      "agents", 
      "expression", 
      "appearance", 
      "cyclic peptides", 
      "presence", 
      "linear peptides", 
      "spheroids", 
      "comparison", 
      "results", 
      "analysis", 
      "growth", 
      "linear homologs", 
      "homolog", 
      "formation", 
      "morphology", 
      "surface", 
      "Treatment of U-87MG", 
      "death of cRGDfV", 
      "intracranial U-87MG tumors", 
      "non-toxic direct anti-tumor therapy", 
      "direct anti-tumor therapy", 
      "Human Malignant Glioma Therapy", 
      "Anti-\u03b1V\u03b23 Integrin Agents", 
      "Integrin Agents"
    ], 
    "name": "Human Malignant Glioma Therapy Using Anti-\u03b1V\u03b23 Integrin Agents", 
    "pagination": "135-144", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045558251"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1006444300504"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10894366"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1006444300504", 
      "https://app.dimensions.ai/details/publication/pub.1045558251"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_323.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1006444300504"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1006444300504'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1006444300504'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1006444300504'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1006444300504'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      22 PREDICATES      123 URIs      111 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1006444300504 schema:about N063a116aea014ea4aa9ae2faefd6c404
2 N0eab740674d348f184a08e2adfcc2567
3 N17ddf373432a4d7a8bd677aae9bab346
4 N1f83563525e54ebbbdf9fb8dfffb5efa
5 N2b9f521d2d534d788dbe7363789eaac4
6 N3ea29dc1193e42eb89b83841c14d362d
7 N446a8778674740b88d5cf6b7407083c4
8 N49fc854f66d641388f9f4270cf07b75e
9 N6081c4a6562d4bd588f410e615df0d10
10 N6c4b4a8257ab40819b35ae58d5f54e33
11 N7716439410504f999a4faf1716cedf09
12 N88c4b445d2d94a98858a44dd48f259ed
13 N8e1ed6fd95e8417ba09b4808f5e4c654
14 Nc2e5dac9fa8447b6be9a1c7811dd7b6a
15 Nd2b7df1805394bb3abb86738fdc9343e
16 Nd4b34c227c81482895069517d1b12abe
17 Nd5aae7b669d44b1e8d9ff0bf2ec0f497
18 Ndf54919d528f465e828d79ac53283ddb
19 Ne8d4fa96fba2491c80f77dca681de9a5
20 Nec7a65a16a064ea4b5f2237c7f0a4db3
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author Nf42c207ecb4947099e0d6a6a3f06edaa
24 schema:citation sg:pub.10.1007/s002620050252
25 sg:pub.10.1038/34214
26 sg:pub.10.1038/356356a0
27 sg:pub.10.1038/nm0498-408
28 schema:datePublished 2000-01
29 schema:datePublishedReg 2000-01-01
30 schema:description Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults and is invariably fatal. We have investigated the effect of cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide on survival of human malignant glioma cells in vitro and in vivo. Immunofluorescent analyses revealed the presence of αVβ3 integrin on U-87MG and U-373MG cells, but minimal expression on U-251MG cells. Treatment of U-87MG and U-373MG cells in vitro with cRGDfV (20 µg/ml), but not the linear peptide, resulted in the appearance of rounded and loosely attached cells with subsequent cell death. By comparison, neither this cyclic peptide nor its linear homolog had any significant effect on growth and morphology of U-251MG cells. The death of cRGDfV-treated (20 µg/ml) glioma cells was blocked by pretreatment (10 µM) of cells with DEVD-FMK and LEHD-FMK, inhibitors of caspase-3 and caspase-9, respectively. Moreover, when glioma cells grown as spheroids were treated with cRGDfV (50 µg/ml), spheroid formation was markedly reduced. Further, treatment of intracranial U-87MG tumors in scid mice with cyclic peptide significantly (p<0.001) prolonged their survival. These results indicated (i) that cRGDfV induced apoptosis of human glioma cells by binding αVβ3 integrin expressed on their cell surfaces and (ii) that cRGDfV may be an effective and non-toxic direct anti-tumor therapy for αVβ3-expressing GBMs.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf N67feec83328e41f7a8d6dc8d7b6f86d8
35 Ndd4f0ae881484145b8f0349020e42f1f
36 sg:journal.1094205
37 schema:keywords Anti-αVβ3 Integrin Agents
38 DEVD-FMK
39 Human Malignant Glioma Therapy
40 Integrin Agents
41 LEHD-FMK
42 SCID mice
43 Treatment of U-87MG
44 U-251MG cells
45 U-373MG cells
46 U-87MG
47 U-87MG tumors
48 adults
49 agents
50 analysis
51 anti-tumor therapy
52 apoptosis
53 appearance
54 brain tumors
55 cRGDfV
56 caspase-3
57 caspase-9
58 cell death
59 cell surface
60 cells
61 comparison
62 cyclic peptides
63 death
64 death of cRGDfV
65 direct anti-tumor therapy
66 effect
67 expression
68 formation
69 frequent malignant brain tumor
70 glioblastoma multiforme
71 glioma cells
72 glioma therapy
73 growth
74 homolog
75 human glioma cells
76 human malignant glioma cells
77 immunofluorescent analysis
78 inhibitor of caspase-3
79 inhibitors
80 integrins
81 intracranial U-87MG tumors
82 linear homologs
83 linear peptides
84 malignant brain tumors
85 malignant glioma cells
86 malignant glioma therapy
87 mice
88 minimal expression
89 morphology
90 multiforme
91 non-toxic direct anti-tumor therapy
92 peptides
93 presence
94 pretreatment
95 pretreatment of cells
96 results
97 significant effect
98 spheroid formation
99 spheroids
100 subsequent cell death
101 surface
102 survival
103 therapy
104 treatment
105 tumors
106 vitro
107 vivo
108 αvβ3 integrin
109 schema:name Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents
110 schema:pagination 135-144
111 schema:productId N0f9360d9f9ee414cbfed937ebc85c554
112 N42c38885990a435db914a93773a1900d
113 Ne5c02faa358446e08b3c0c18287138c1
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045558251
115 https://doi.org/10.1023/a:1006444300504
116 schema:sdDatePublished 2021-12-01T19:11
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N0d38ca03541b4c39b171092bd1d0e04a
119 schema:url https://doi.org/10.1023/a:1006444300504
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N063a116aea014ea4aa9ae2faefd6c404 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Spheroids, Cellular
125 rdf:type schema:DefinedTerm
126 N06cc9189ce1a4c4b9be96495210a709a rdf:first Ndae436bb809249b2a48e228d87a1256f
127 rdf:rest N3c03fb80c6e24ad88bdca6e27591f497
128 N0d38ca03541b4c39b171092bd1d0e04a schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N0eab740674d348f184a08e2adfcc2567 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Cell Division
132 rdf:type schema:DefinedTerm
133 N0f9360d9f9ee414cbfed937ebc85c554 schema:name dimensions_id
134 schema:value pub.1045558251
135 rdf:type schema:PropertyValue
136 N17ddf373432a4d7a8bd677aae9bab346 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Animals
138 rdf:type schema:DefinedTerm
139 N1f83563525e54ebbbdf9fb8dfffb5efa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Peptides, Cyclic
141 rdf:type schema:DefinedTerm
142 N2b9f521d2d534d788dbe7363789eaac4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Oligopeptides
144 rdf:type schema:DefinedTerm
145 N3c03fb80c6e24ad88bdca6e27591f497 rdf:first Ndd813bbd2a184f99a31dd5c6212921bf
146 rdf:rest Nff07ce43ddab41c4b9061b3fd9630600
147 N3ea29dc1193e42eb89b83841c14d362d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Brain Neoplasms
149 rdf:type schema:DefinedTerm
150 N42c38885990a435db914a93773a1900d schema:name pubmed_id
151 schema:value 10894366
152 rdf:type schema:PropertyValue
153 N446a8778674740b88d5cf6b7407083c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Enzyme Inhibitors
155 rdf:type schema:DefinedTerm
156 N49fc854f66d641388f9f4270cf07b75e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Mice
158 rdf:type schema:DefinedTerm
159 N6081c4a6562d4bd588f410e615df0d10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Neoplasm Transplantation
161 rdf:type schema:DefinedTerm
162 N67feec83328e41f7a8d6dc8d7b6f86d8 schema:issueNumber 2
163 rdf:type schema:PublicationIssue
164 N6c4b4a8257ab40819b35ae58d5f54e33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Caspase 9
166 rdf:type schema:DefinedTerm
167 N7716439410504f999a4faf1716cedf09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Glioma
169 rdf:type schema:DefinedTerm
170 N88c4b445d2d94a98858a44dd48f259ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Caspase 3
172 rdf:type schema:DefinedTerm
173 N8e1ed6fd95e8417ba09b4808f5e4c654 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Injections, Intralesional
175 rdf:type schema:DefinedTerm
176 Nc2e5dac9fa8447b6be9a1c7811dd7b6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Cell Membrane
178 rdf:type schema:DefinedTerm
179 Nd2b7df1805394bb3abb86738fdc9343e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Caspase Inhibitors
181 rdf:type schema:DefinedTerm
182 Nd4b34c227c81482895069517d1b12abe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Cell Survival
184 rdf:type schema:DefinedTerm
185 Nd5aae7b669d44b1e8d9ff0bf2ec0f497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Mice, SCID
187 rdf:type schema:DefinedTerm
188 Ndae436bb809249b2a48e228d87a1256f schema:affiliation grid-institutes:grid.459663.b
189 schema:familyName Matsumura
190 schema:givenName Akiko
191 rdf:type schema:Person
192 Ndd4f0ae881484145b8f0349020e42f1f schema:volumeNumber 46
193 rdf:type schema:PublicationVolume
194 Ndd813bbd2a184f99a31dd5c6212921bf schema:affiliation grid-institutes:None
195 schema:familyName Schradermeier
196 schema:givenName Jaime
197 rdf:type schema:Person
198 Ndf54919d528f465e828d79ac53283ddb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Receptors, Vitronectin
200 rdf:type schema:DefinedTerm
201 Ne5c02faa358446e08b3c0c18287138c1 schema:name doi
202 schema:value 10.1023/a:1006444300504
203 rdf:type schema:PropertyValue
204 Ne8d4fa96fba2491c80f77dca681de9a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Humans
206 rdf:type schema:DefinedTerm
207 Nec7a65a16a064ea4b5f2237c7f0a4db3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Tumor Cells, Cultured
209 rdf:type schema:DefinedTerm
210 Nf42c207ecb4947099e0d6a6a3f06edaa rdf:first sg:person.01102520331.50
211 rdf:rest N06cc9189ce1a4c4b9be96495210a709a
212 Nff07ce43ddab41c4b9061b3fd9630600 rdf:first sg:person.0734755026.80
213 rdf:rest rdf:nil
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
218 schema:name Oncology and Carcinogenesis
219 rdf:type schema:DefinedTerm
220 sg:journal.1094205 schema:issn 0167-594X
221 1573-7373
222 schema:name Journal of Neuro-Oncology
223 schema:publisher Springer Nature
224 rdf:type schema:Periodical
225 sg:person.01102520331.50 schema:affiliation grid-institutes:None
226 schema:familyName Chatterjee
227 schema:givenName Subhendra
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102520331.50
229 rdf:type schema:Person
230 sg:person.0734755026.80 schema:affiliation grid-institutes:grid.265892.2
231 schema:familyName Gillespie
232 schema:givenName G. Yancey
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734755026.80
234 rdf:type schema:Person
235 sg:pub.10.1007/s002620050252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027317999
236 https://doi.org/10.1007/s002620050252
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/34214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029180304
239 https://doi.org/10.1038/34214
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/356356a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010557586
242 https://doi.org/10.1038/356356a0
243 rdf:type schema:CreativeWork
244 sg:pub.10.1038/nm0498-408 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003109127
245 https://doi.org/10.1038/nm0498-408
246 rdf:type schema:CreativeWork
247 grid-institutes:None schema:alternateName JCR Biopharmaceuticals, Inc., San Diego, CA, USA
248 schema:name JCR Biopharmaceuticals, Inc., San Diego, CA, USA
249 rdf:type schema:Organization
250 grid-institutes:grid.265892.2 schema:alternateName ivision of Neurosurgery, Brain Tumor Research Laboratories, University of Alabama at Birmingham, Birmingham, AL, USA
251 schema:name ivision of Neurosurgery, Brain Tumor Research Laboratories, University of Alabama at Birmingham, Birmingham, AL, USA
252 rdf:type schema:Organization
253 grid-institutes:grid.459663.b schema:alternateName JCR Pharmaceuticals Co., Ltd., Ashiya, Japan
254 schema:name JCR Pharmaceuticals Co., Ltd., Ashiya, Japan
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...